Sun Pharma Advanced Research Company Ltd consolidated sales down 24.77% on year in Q3FY2026, net profit rose by 17.37%,
Sun Pharma Advanced Research Company Ltd share price slipped 1.02% to Rs 175.1 after the company`s net profit registered a growth of 17.37% to Rs 24.39 crore, while revenue from operations nosedived 24.77% to Rs 30.03 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, rising 4.75%. It has improved by 2.16% over last one week and gained upto 0.86% in last one month while the market capitalization of Sun Pharma Advanced Research Company Ltd has eased by 1.90% and 19.75% in the same period respectively. Profit before tax (PBT) of Sun Pharma Advanced Research Company Ltd stood at Rs 24.31 crore in Q3 FY26, tumbling by 67.92% year-on-year, and expanding by 17.61% quarter-on-quarter. EBITDA came in at Rs 69 crore, gaining 5.32% YoY and rallying 20.07% sequentially. Total expenses saw a slight increase of 2.26% to Rs 77.84 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 9.95 crore, surging by 29.90% YoY, while employee benefits expense was at Rs 29.33 crore, softening 0.95% YoY. For the TTM ended FY26, revenue from operations plunged by 45.45% to Rs 39.15 crore, while net profit witnessed a sharp fall of 553.48% to Rs 1553.2 crore, compared to previous TTM. EBITDA tanked by 32811% to Rs 1587.81 crore, and PBT tumbled by 553.06% to Rs 1553.01 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 238.77 crore in FY26, as against Rs 360.29 crore in FY25. Sun Pharma Advanced Research Company Ltd jumped 24.89% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 9.87% during the same period.
Sun Pharma Advanced Research to review financial results at board meeting November 2, 2026,
Sun Pharma Advanced Research Company Ltd will hold a board meeting on Monday, November 02, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing with the National Stock Exchange of India Ltd and BSE Limited. The trading window for company shares has been closed for directors, key managerial personnel, designated employees, and connected persons from October 01, 2026, and will remain closed until 48 hours after the financial results are declared and submitted to the stock exchanges.
Sun Pharma Advanced Research submitted a certificate to the NSE and BSE for Q3 2026,
Sun Pharma Advanced Research Company Ltd. submitted a confirmation certificate to the National Stock Exchange of India Ltd. and BSE Limited for the quarter ended September 30, 2026, as per Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, with MUFG Intime (India) Private Limited acting as the Registrar and Share Transfer Agent.
Sun Pharma Advanced Research closes share trading window ahead of financial results,
Sun Pharma Advanced Research Company Limited informed the National Stock Exchange of India Ltd. and BSE Limited that the trading window for dealing in the company’s shares will be closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the second quarter and half year ended September 30, 2026.
Sun Pharma Advanced Research Company reports consolidated net loss of Rs 20.78 crore in the June 2026 quarter,
Net Loss of Sun Pharma Advanced Research Company reported to Rs 20.78 crore in the quarter ended June 2026 as against net loss of Rs 51.87 crore during the previous quarter ended June 2025. Sales rose 314.11% to Rs 39.92 crore in the quarter ended June 2026 as against Rs 9.64 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales39.929.64 314 OPM %-85.17-540.25 - PBDT-18.47-49.13 62 PBT-20.67-51.81 60 NP-20.78-51.87 60 Powered by Capital Market - Live News
Subscribe for our
newsletter
Open Account Now